Reversal of Tau-Dependent Cognitive Decay by Blocking Adenosine A1 Receptors: Comparison of Transgenic Mouse Models with Different Levels of Tauopathy
暂无分享,去创建一个
A. Drzezga | E. Mandelkow | E. Mandelkow | H. Endepols | B. Neumaier | S. Kaniyappan | A. Sydow | M. Anglada-Huguet | Ronja Hilgers
[1] Joanne Baltos,et al. Adenosine receptor signalling in Alzheimer’s disease , 2022, Purinergic Signalling.
[2] O. Piguet,et al. Olfactory Bulb Integrity in Frontotemporal Dementia and Alzheimer's Disease. , 2022, Journal of Alzheimer's disease : JAD.
[3] D. Geschwind,et al. Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration , 2022, Cell.
[4] B. Bardoni,et al. Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders , 2021, Molecular Psychiatry.
[5] D. Attwell,et al. Brain’s immune cells put the brakes on neurons , 2020, Nature.
[6] Ukpong B. Eyo,et al. Negative feedback control of neuronal activity by microglia , 2020, Nature.
[7] K. Ashe,et al. Factors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice , 2019, Nature Communications.
[8] Y. Bouter,et al. 18F-FDG-PET in Mouse Models of Alzheimer's Disease , 2019, Front. Med..
[9] E. Mandelkow,et al. Screening of a neuronal cell model of tau pathology for therapeutic compounds , 2019, Neurobiology of Aging.
[10] C. Murphy. Olfactory and other sensory impairments in Alzheimer disease , 2018, Nature Reviews Neurology.
[11] E. Sigurdsson,et al. Tau-targeting therapies for Alzheimer disease , 2018, Nature Reviews Neurology.
[12] P. Verstreken,et al. Synaptogyrin-3 Mediates Presynaptic Dysfunction Induced by Tau , 2018, Neuron.
[13] E. Mandelkow,et al. Anti-aggregant tau mutant promotes neurogenesis , 2017, Molecular Neurodegeneration.
[14] Christoforos Hadjichrysanthou,et al. Why do so many clinical trials of therapies for Alzheimer's disease fail? , 2017, The Lancet.
[15] A. Blockeel,et al. Tracking progressive pathological and functional decline in the rTg4510 mouse model of tauopathy , 2017, Alzheimer's Research & Therapy.
[16] F. Cayabyab,et al. Adenosine A1 and A2A Receptors in the Brain: Current Research and Their Role in Neurodegeneration , 2017, Molecules.
[17] A. Giralt,et al. Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticity , 2016, Neurobiology of Disease.
[18] E. Mandelkow,et al. Adenosine A1 receptor antagonist rolofylline alleviates axonopathy caused by human Tau ΔK280 , 2016, Proceedings of the National Academy of Sciences.
[19] E. Mandelkow,et al. Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau , 2015, Acta neuropathologica communications.
[20] M. Frotscher,et al. Pro-aggregant Tau impairs mossy fiber plasticity due to structural changes and Ca++ dysregulation , 2015, Acta neuropathologica communications.
[21] Bradley T. Hyman,et al. The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease , 2014, Neuron.
[22] C. Harrington,et al. Tau-aggregation inhibitor therapy for Alzheimer's disease. , 2014, Biochemical pharmacology.
[23] A. Giralt,et al. Prostaglandin E2 EP1 Receptor Antagonist Improves Motor Deficits and Rescues Memory Decline in R6/1 Mouse Model of Huntington's Disease , 2014, Molecular Neurobiology.
[24] K. Jellinger,et al. Olfactory bulb involvement in neurodegenerative diseases , 2014, Acta Neuropathologica.
[25] J. Kuret,et al. Structural Determinants of Tau Aggregation Inhibitor Potency* , 2013, The Journal of Biological Chemistry.
[26] E. Mandelkow,et al. Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology , 2013, The FEBS journal.
[27] E. Mandelkow,et al. Cascade of tau toxicity in inducible hippocampal brain slices and prevention by aggregation inhibitors , 2013, Neurobiology of Aging.
[28] E. Mandelkow,et al. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. , 2012, Cold Spring Harbor perspectives in medicine.
[29] I. Pérez-Otaño,et al. Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease , 2012, Hippocampus.
[30] R. D'Hooge,et al. Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau , 2012, Acta Neuropathologica.
[31] F. van Leuven,et al. Early Improved and Late Defective Cognition Is Reflected by Dendritic Spines in Tau.P301L Mice , 2011, The Journal of Neuroscience.
[32] B. Strooper,et al. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.
[33] R. D'Hooge,et al. Reversibility of Tau-Related Cognitive Defects in a Regulatable FTD Mouse Model , 2011, Journal of Molecular Neuroscience.
[34] Weifeng Xu,et al. PSD-95-like membrane associated guanylate kinases (PSD-MAGUKs) and synaptic plasticity , 2011, Current Opinion in Neurobiology.
[35] Rudi D'Hooge,et al. Tau-Induced Defects in Synaptic Plasticity, Learning, and Memory Are Reversible in Transgenic Mice after Switching Off the Toxic Tau Mutant , 2011, The Journal of Neuroscience.
[36] P. Ponikowski,et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. , 2010, The New England journal of medicine.
[37] B. Hocher,et al. Adenosine A1 receptor antagonists in clinical research and development. , 2010, Kidney international.
[38] Hsiao-Wen Chen,et al. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system. , 2009, Human molecular genetics.
[39] T. Ma,et al. Synaptic Activity Reduces Intraneuronal Aβ, Promotes APP Transport to Synapses, and Protects against Aβ-Related Synaptic Alterations , 2009, The Journal of Neuroscience.
[40] Stephen M. Smith,et al. Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference , 2009, NeuroImage.
[41] L. Costantini,et al. Hypometabolism as a therapeutic target in Alzheimer's disease , 2008, BMC Neuroscience.
[42] H. Bujard,et al. The Potential for β-Structure in the Repeat Domain of Tau Protein Determines Aggregation, Synaptic Decay, Neuronal Loss, and Coassembly with Endogenous Tau in Inducible Mouse Models of Tauopathy , 2008, The Journal of Neuroscience.
[43] Ping Huang,et al. Metabolic control of proteasome function. , 2007, Physiology.
[44] Hermann Bujard,et al. The β-Propensity of Tau Determines Aggregation and Synaptic Loss in Inducible Mouse Models of Tauopathy* , 2007, Journal of Biological Chemistry.
[45] S. Santi,et al. Early detection of Alzheimer’s disease using neuroimaging , 2007, Experimental Gerontology.
[46] M. Ohno,et al. Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.
[47] K. Ashe,et al. Age-Dependent Neurofibrillary Tangle Formation, Neuron Loss, and Memory Impairment in a Mouse Model of Human Tauopathy (P301L) , 2005, The Journal of Neuroscience.
[48] B. Hyman,et al. Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function , 2005, Science.
[49] R. D'Hooge,et al. Neurocognitive and Psychotiform Behavioral Alterations and Enhanced Hippocampal Long-Term Potentiation in Transgenic Mice Displaying Neuropathological Features of Human α-Mannosidosis , 2005, The Journal of Neuroscience.
[50] J. D. McGaugh,et al. Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-Related Cognitive Deficits in Transgenic Mice , 2005, Neuron.
[51] O. Vitolo,et al. Dendrite and dendritic spine alterations in alzheimer models , 2004, Journal of neurocytology.
[52] K. Herholz,et al. Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[53] Y. Dudai. The neurobiology of consolidations, or, how stable is the engram? , 2004, Annual review of psychology.
[54] F. LaFerla,et al. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease , 2003, Neurobiology of Aging.
[55] Horst Halling,et al. Evaluation of 18F-CPFPX, a novel adenosine A1 receptor ligand: in vitro autoradiography and high-resolution small animal PET. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[56] Karl Zilles,et al. In vivo imaging of adenosine A1 receptors in the human brain with [18F]CPFPX and positron emission tomography , 2003, NeuroImage.
[57] M. Mattson,et al. Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.
[58] J. Hardy,et al. The relationship between amyloid and tau , 2003, Journal of Molecular Neuroscience.
[59] Gary K. Beauchamp,et al. Food Intake, Water Intake, and Drinking Spout Side Preference of 28 Mouse Strains , 2002, Behavior genetics.
[60] A. Ciechanover,et al. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. , 2002, Physiological reviews.
[61] G. Alexander,et al. Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[62] J. Buccafusco. Methods of Behavior Analysis in Neuroscience , 2000 .
[63] Patrick R. Hof,et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders 1 1 These authors contributed equally to this work. , 2000, Brain Research Reviews.
[64] J. Mazziotta,et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[65] E. Mandelkow,et al. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[66] Y. Sekino,et al. Cellular localization of adenosine A1 receptors in rat forebrain: Immunohistochemical analysis using adenosine A1 receptor‐specific monoclonal antibody , 1999, The Journal of comparative neurology.
[67] E. Kandel,et al. Control of Memory Formation Through Regulated Expression of a CaMKII Transgene , 1996, Science.
[68] H. Kase,et al. KW‐3902, a selective high affinity antagonist for adenosine A1 receptors , 1996, British journal of pharmacology.
[69] B. Gähwiler,et al. Comparison of the actions of adenosine at pre‐ and postsynaptic receptors in the rat hippocampus in vitro. , 1992, The Journal of physiology.
[70] R. Morris. Developments of a water-maze procedure for studying spatial learning in the rat , 1984, Journal of Neuroscience Methods.
[71] B. Reisberg,et al. Regional correlation of PET and CT in senile dementia of the Alzheimer type. , 1983, AJNR. American journal of neuroradiology.
[72] Edmund M. Glaser,et al. Analysis of thick brain sections by obverse—Reverse computer microscopy: Application of a new, high clarity Golgi—Nissl stain , 1981, Journal of Neuroscience Methods.
[73] J. Götz,et al. Experimental Models of Tauopathy - From Mechanisms to Therapies. , 2019, Advances in experimental medicine and biology.
[74] R. D'Hooge,et al. A2A adenosine receptor deletion is protective in a mouse model of Tauopathy , 2016, Molecular Psychiatry.
[75] A. Takashima. Tauopathies and tau oligomers. , 2013, Journal of Alzheimer's disease : JAD.
[76] Carlo Caltagirone,et al. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.
[77] D. Holtzman,et al. Deciphering Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[78] K. Browman,et al. Cued and Contextual Fear Conditioning for Rodents , 2009 .
[79] T. Abel,et al. Regulation of hippocampus-dependent memory by cyclic AMP-dependent protein kinase. , 2008, Progress in brain research.
[80] T. Dunwiddie,et al. The Role and Regulation of Adenosine in the Central Nervous System , 2022 .
[81] JoVE Video Dataset , 2022 .